healthcare

Review
Prevention and Treatment of Phlebitis Secondary to the
Insertion of a Peripheral Venous Catheter: A Scoping Review
from a Nursing Perspective
Aitana Guanche-Sicilia 1,† , María Begoña Sánchez-Gómez 2,† , María Elisa Castro-Peraza 2 ,
José Ángel Rodríguez-Gómez 3 , Juan Gómez-Salgado 4,5, * and Gonzalo Duarte-Clíments 2

1 University Hospital Nuestra Señora de Candelaria, Canary Islands Health Service, 38010 Tenerife, Spain;
[email protected]
2 University School of Nursing Nuestra Señora de Candelaria, University of La Laguna, 38001 Tenerife, Spain;
[email protected] (M.B.S.-G.); [email protected] (M.E.C.-P.); [email protected] (G.D.-C.)
3 Chair of Nursing, Faculty of Health Sciences, University of La Laguna, 38001 Tenerife, Spain;
[email protected]
4 Department of Sociology, Social Work and Public Health. Faculty of Labour Sciences, University of Huelva,
21007 Huelva, Spain
5 Safety and Health Postgraduate Programme, Universidad Espíritu Santo, 092301 Guayaquil, Ecuador
* Correspondence: [email protected]; Tel.: +34-959219700



† These authors are co-first authors, as they contributed equally to this work.



Citation: Guanche-Sicilia, A.; Abstract: The objective of this work was to identify available evidence on nursing interventions for
Sánchez-Gómez, M.B.; Castro-Peraza, the prevention and treatment of phlebitis secondary to the insertion of a peripheral venous catheter.
M.E.; Rodríguez-Gómez, J.Á.; Gómez- For this, a scoping systematic review was carried out following the guidelines in the PRISMA
Salgado, J.; Duarte-Clíments, G. declaration of documents published between January 2015 and December 2020. The search took
Prevention and Treatment of Phlebitis
place between December 2020 and January 2021. Scielo, Pubmed, Medline, Scopus, WOS, CINHAL,
Secondary to the Insertion of a
LILACS, and Dialnet databases were consulted, and CASPe, AGREE, and HICPAC tools were used
Peripheral Venous Catheter: A
for the critical reading. A total of 52 studies were included to analyze nursing interventions for
Scoping Review from a Nursing
treatment and prevention. Nursing interventions to prevent phlebitis and ensure a proper catheter
Perspective. Healthcare 2021, 9, 611.
https://doi.org/10.3390/healthcare
use included those related to the maintenance of intravenous therapy, asepsis, and choosing the
9050611 dressing. With regard to the nursing interventions to treat phlebitis, these were focused on vigilance
and caring and also on the use of medical treatment protocols. For the prevention of phlebitis, the
Academic Editors: Francesco highest rated evidence regarding asepsis include the topical use of >0.5% chlorhexidine preparation
Cacciatore and Akira Sekikawa with 70% alcohol or 2% aqueous chlorhexidine, a proper hygienic hand washing, and the use clean
gloves to handle connections and devices. Actions that promote the efficacy and safety of intravenous
Received: 3 March 2021 therapy include maintenance of venous access, infusion volume control, verification of signs of
Accepted: 14 May 2021 phlebitis during saline solution and medication administration, and constant monitoring. It is
Published: 19 May 2021
recommended to remove any catheter that is not essential. Once discharged from hospital, it will be
necessary to warn the patient about signs of phlebitis after PVC removal.
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
Keywords: phlebitis; catheters; nursing care; patient-centered care; patient safety; evidence-based practice
published maps and institutional affil-
iations.

1. Introduction
Vascular access cannulation through the use of peripheral venous catheters (PVCs) is
Copyright: © 2021 by the authors.
a common practice and is considered the most common invasive procedure performed on
Licensee MDPI, Basel, Switzerland.
This article is an open access article
hospitalized patients [1]. This technique allows quick access to the vascular system, being
distributed under the terms and
less invasive and less complex than other techniques [1–3]. The type of catheter is chosen
conditions of the Creative Commons
based on the estimated duration and type of treatment to be infused, and among the uses
Attribution (CC BY) license (https:// of PVCs are fluid therapy, parenteral nutrition, blood products, and diagnostic tests [4].
creativecommons.org/licenses/by/ The most common side effect of PVC is phlebitis [5]. This consists of acute inflamma-
4.0/). tion of the wall of the blood vessels, with irritation of the venous endothelium in the section

Healthcare 2021, 9, 611. https://doi.org/10.3390/healthcare9050611 https://www.mdpi.com/journal/healthcare

Healthcare 2021, 9, 611 2 of 24

or segment cannulated by the catheter [6]. Identification of phlebitis requires assessment of

possible signs and symptoms present in the insertion area, such as erythema, tumefaction
in the vein, pain, heat, and fever [7]. In this sense, the use of rating scales such as the
Visual Infusion Phlebitis (VIP) scale, the Phlebitis scale, and the Maddox scale [8–10] may
be useful.
In Spain, up to 30% of the bacteriaemia associated with hospital care is related to the
use of intravascular devices, and these produce increased morbidity and hospital expenses,
which are estimated at around 18,000 euros per episode [4].
PVC management is an under-recognized issue regarding patient risk within the
complexity of care [11]. It was verified through the National Study of Adverse Events
(ENEAS, for its acronym in Spanish) that if phlebitis is included as an adverse healthcare
event, it would rank first followed by medication errors, infections arising from healthcare-
related practices, and surgical techniques [7]. On the other hand, the SENECA Project:
Quality of care standards for patient safety in National Health System hospitals, enabled
from 1344 revised medical records, from 32 different hospitals, identified approximately
377 patients who developed phlebitis and/or extravasation (25.1%) [7]. Phlebitis prolongs
hospitalization and treatment, increases economic expenses, decreases patient satisfaction,
and can lead to other complications such as sepsis, pain, discomfort, stress, possibility of
clotting, thrombophlebitis, and embolism [5,12,13].
The Infusion Nurses Society (INS) [9] indicates that the accepted phlebitis rate should
be 5% or less [14,15]. Currently, a phlebitis incidence of 0.5% to 59.1% [5] is estimated, with
a prevalence of between 20 and 80% of patients following intravenous treatment [16].
Nurses’ knowledge on the proper management of PVC and early recognition of
risk factors can reduce these complications [14,17]. In Spain, it is a nursing competence,
collected in Order CIN/2134/2008, of 3 July [18]. In addition, the North American Nursing
Diagnosis Association (NANDA-I) collects a risk diagnosis to prevent risk of (00213)
phlebitis, and the Nursing Intervention Classification (NIC) establishes interventions
for the prevention and treatment of phlebitis such as (4200) Intravenous therapy (iv);
(2314) Medication administration: intravenous (iv); and (4235) Phlebotomy: Cannulated
Vessel [19,20].
For this reason, the objective of this review was to identify available evidence on
nursing interventions for the prevention and treatment of phlebitis secondary to the
insertion of a peripheral venous catheter.

2. Materials and Methods

2.1. Design
A systematic scoping review [21] of the literature was carried out, following the
standards set out in the PRISMA extension for Scoping Reviews (PRISMA-ScR) [22]. Based
on the PICO format (Table 1), the following research question was developed: What are
the evidence-based nursing interventions for the prevention and treatment of phlebitis in patients
with PVC?

Table 1. PICO.

Patient Patients with Peripheral Venous Catheter

Evidence-based nursing interventions for the prevention and treatment
Intervention
of phlebitis
Comparison Non-evidence-based routine interventions
Use of sterile and transparent dressing, catheter size, use of hot and cold
Outcomes compresses, topical treatment, management and maintenance of
intravenous therapy
Healthcare 2021, 9, 611 3 of 24

2.2. Search Strategy

The search was performed between December 2020 and January 2021 (Table 2). The
databases consulted were Scielo, Pubmed, Medline, Scopus, WOS, CINHAL, LILACS, and
Dialnet using MeSH and DeCS descriptors (Table 2).

Table 2. Search strategy.

Date
Database Search Strategy Found Articles Pre-Selected Articles
(dd/mm/yyyy)
Scielo 7/12/2020 Phlebitis AND catheter 19 10
Scielo 02/01/2021 Phlebitis AND treatment 5 1
Scopus 7/12/2020 Phlebitis and nurs* 20 6
Scopus 02/01/2021 Phlebitis AND treatment 6 1
Pubmed 2/12/2020 Phlebitis and nurs* 20 6
Pubmed 12/12/2020 Phlebitis AND intervention AND nurs* 2 1
Pubmed 21/12/2020 Phlebitis AND nurs* intervention 17 2
Pubmed 21/12/2020 Phlebitis AND assessment measure 1 1
Pubmed 13/01/2021 Phlebitis AND prevention AND nurs* 5 1
Pubmed 25/11/2020 Competence AND nurs* AND phlebitis 13 5
Dialnet 13/12/2020 Phlebitis AND nursing 13 3
Medline 13/12/2020 Phlebitis and nursing interventions 2 2
Medline 19/12/2020 Phlebitis and nurs* 64 8
Phlebitis AND treatment OR
Medline 19/12/2020 41 2
intervention OR therapy AND nurs*
WOS 21/01/2021 Phlebitis AND nurs* AND prevention 15 5
WOS 21/01/2021 Phlebitis AND treatment AND nurs* 15 2
LILACS 21/12/2020 Phlebitis AND nursing 65 8
LILACS 21/12/2020 Phlebitis and intervention 3 1
Phlebitis AND treatment OR
CINHAL 02/01/2021 27 5
intervention OR therapy AND nurs*
CINAHL 02/01/2021 Phlebitis AND intervention 23 1
Total 376 71

2.3. Selection Criteria

The search was limited to full-text documents, in Spanish, English, and/or Portuguese,
published in the last 5 years. These included empirical studies and clinical guidelines
that focused on phlebitis, its classification, diagnosis, prevention, and treatment from the
nursing competence perspective. Those that, during the critical reading, did not meet the
expected criteria in the first three questions of the CASPe [23] tool nor of Berra et al.’s
instrument [24] for descriptive articles were excluded. Articles not available in full text and
published in languages other than Spanish, English, or Portuguese were also excluded.
Following the recommendations for improvement for Scoping Reviews by Levac,
Colquon, and O’Brien [25], it was decided not to discriminate by type of study in the
selection. In the classification and presentation of results, we differentiate according to the
design of the selected studies.

2.4. Data Collection and Extraction

The search was conducted independently and pooled by the researchers as detailed
in the Authors Contributions. The authors performed an evidence synthesis by peer
evaluation, analyzing each intervention and evidence individually, following the criteria
provided by the Joanna Briggs Institute (JBI). The discrepancies were jointly discussed to
reach consensus on the degree of evidence (DE) and the degree of recommendation (DR).
Healthcare 2021, 9, 611 4 of 24

2.5. Evaluation of Methodological Quality

Once the titles and summaries of the articles were critically read, data were classified
according to the objectives of the study. The included full-text articles were assessed with
the CASPe [23] and Berra et al.’s [24] tools. For clinical practice guidelines, AGREE [26] was
used for critical reading and the HICPAC system for evidence synthesis [27]. The JBI [28]
criteria were used to classify the degree of evidence (DE) and the degree of recommendation
(DR) of nursing interventions.

3. Results
The number of records identified in the databases was 376, to which five more records
were added by referential search to introduce the clinical practice guidelines, for a total of
381 references. Of the 381 identified references, 52 studies were finally selected according
to eligibility criteria (Figure 1) [22].

Figure 1. Search results (PRISMA flowchart).

In terms of typology, 9 randomized clinical trials, 17 cohort studies, 8 systematic

reviews, 3 case and control studies, 1 qualitative study, 10 descriptive studies, and 4 clinical
practice guidelines, out of the total of 52 selected studies were included. Table 3 lists the
characteristics of the studies included in the scoping review classified according to the type
of article.
Healthcare 2021, 9, 611 5 of 24

Table 3. Characteristics of the studies included in the scoping review.

a. RESULTS FROM CLINICAL STUDIES

JBI Synthesis of
Year and Author Objective Type of Study Results Critical Reading
the Evidence
Protocols with measures such as
Evaluate the incidence of
continuous observation of the insertion
complications related to
Reichembach-Danski et al., site, keeping the catheter insertion site
peripheral intravenous Prospective cohort study 9/11 **** DE*: 3c DR: A
2016 [29] visible, and saline solution infusion prior
catheter use in neonates and
to the administration of other substances
identify associated risk factors.
may be used to reduce complications.
To improve quality of care and prevent
phlebitis and infiltrations, the nurse
should analyze patient characteristics,
prescribed intravenous medications
(irritant and/or vesicant, pH, and
Determine the incidence rate
osmolarity), expected duration of
and risk factors for phlebitis
intravenous treatment, and risk factors
Braga et al., 2018 [30] and infiltration in patients Cohort study 9/11 **** DE*: 3c DR: A
for complications that can occur before
with peripheral
selecting a venous catheter. Evaluate
venous catheter.
risks and benefits of each type of
catheter and consider patient
preferences. This test may indicate the
use of other venous catheters, such as
peripherally inserted central catheter.
Describe cases of phlebitis Knowing the characteristics of phlebitis
reported in a university favors understanding and minimization
Rosário-Pereira et al., 2019 Retrospective, Intermediate evidence
hospital and contribute to of this adverse event so as to establish DE*: 3e DR: A
[31] observational study *****
possible improvement actions preventive behaviors and decrease risk
in quality of care and safety. and incidence.
Project to improve visibility of
intravenous area through the
Improved visibility of the intravenous
use of transparent adhesive
puncture site and nurses’ compliance in
dressings to achieve frequent
Lim et al., 2018 [32] Quasi-experimental study frequent testing and monitoring; 8/11 **** DE*: 2d DR: B
and adequate intravenous
phlebitis can be detected early, reducing
inspection of the intravenous
severity of complications.
area and reduce incidence
of complications.
Healthcare 2021, 9, 611 6 of 24

Table 3. Cont.

Assess whether the use of a

skin adhesive glue to secure a
Adding a drop of cyanoacrylate
peripheral intravenous line
Bugden et al., 2016 [33] Randomized clinical trial adhesive helps stabilize the peripheral 9/11 **** DE*: 1c DR: A
improves failure rates
intravenous catheter.
compared with standard
securing measures
Evaluate efficacy of I.V I.V House UltraDressing device is useful
UltraDressing to protect to increase catheter dwell time and
Büyükyılmaz et al., 2019 [34] Randomized clinical trial 9/11 **** DE*: 1c DR: A
peripheral intravenous protect and stabilize PVCs in
catheters in pediatric patients. pediatric patients.
A hot water compress is useful in the
Assess the effectiveness of
treatment of phlebitis and could
Annisa et al., 2017 [35] applying hot compress to Quasi-experimental study 8/11 **** DE*: 2d DR: A
decrease degree of phlebitis in an
reduce the degree of phlebitis.
effective and cost-saving way.
Complementary methods for the
Assess the effects of topical
treatment of phlebitis symptoms are
Bigdeli-Shamloo et al., sesame oil on reduced severity
Randomized clinical trial proposed. Application of sesame oil is 9/11 **** DE*: 1c DR: A
2019 [36] of "chemotherapy-induced
effective in reducing severity of
phlebitis" pain.
chemotherapy-induced phlebitis pain.
Assess the effect of topical
Topical chamomile may be effective in
chamomile on phlebitis caused
Sharifi-Ardani et al., 2017 [37] Randomized clinical trial decreasing incidence of phlebitis for its 9/11 **** DE*: 1c DR: A
by the administration of
anti-inflammatory capacity.
amiodarone infusion in PVC.
During the inclusion period for Burow
solution in 35 patients with phlebitis, 12
have been excluded for lack of follow-up.
Describe the use and assess
83% (n = 19) have responded to the
García-Quintanilla et al., the efficacy and safety of Prospective observational
therapy by reducing the degree of 7/11 **** DE*: 3e DR: A
2018 [38] Burow solution for topical study
phlebitis by two points after three days
treatment of phlebitis.
of treatment, and 17% (n = 4) were
unresponsive, requiring topical
applications of Feparil®.
Healthcare 2021, 9, 611 7 of 24

Table 3. Cont.

Applying marigold ointment decreased

Compare the effect of wet
the severity of phlebitis in a shorter
compresses and marigold
period, compared to using a wet, hot
Jourabloo et al., 2017 [39] ointment on the severity of Randomized clinical trial 9/11 **** DE*: 1c DR: A
compress. This ointment is
phlebitis caused by
recommended to reduce
dextrose infusion.
phlebitis severity.
Establish clinical efficacy and
Developing a double-pump syringe
safety parameters for
makes it easier for nurses to adopt good
double-pump syringes for DE: 1c *
Parreira et al., 2020 [40] Randomized clinical trial clinical practices in procedures and 8/11 ****
intravenous medication DR: A
administer intravenous medicine to
administration and
reduce catheter handling.
PVC washing.
No statistically significant differences
Compare rates of phlebitis and
were found in frequency of phlebitis and
catheter tip colonization
PVC tip colonisation regarding blockage
between PVC blocked with DE: 1c *
Pérez-Granda et al., 2020 [41] Randomized clinical trial with saline solution or with heparin. 8/11 ****
saline solution and blocked DR: A
PVC can be maintained with saline
with heparin in patients
solution, and it is safer and cheaper
admitted to internal medicine.
than heparin.
b. RESULTS FROM REVIEWS
JBI Synthesis of
Year and Author Research Question Methodology Results Critical Reading
the Evidence
Intravenous catheters not secured
properly produce higher rates of
Assess complications
mechanical phlebitis and infection.
associated with improperly
Clinical staff need to be educated on DE*: 4a
Higgingson, 2015 [42] secured intravenous cannulae, Literature review 8/11 ****
PVC stabilization as an important DR: A
along with examination of
measure to reduce phlebitis. Safety
fastening devices.
devices are available for their use
whenever appropriate.
Healthcare 2021, 9, 611 8 of 24

Table 3. Cont.

Continuous training and evaluation are

Provide summarized evidence
needed on handling, aseptic technique
on intravascular device Best practice
Chau and Pellowe, 2008 [43] and hand washing, choosing a catheter Recommended *** DR: A *
management to reduce risk information sheet
based on estimated function, duration,
of infection.
and complications.
Provide summarized evidence
on intravascular device Best practice
Chau and Pellowe, 2008 [43] Flush stopcocks with saline solution. Recommended *** DR: B *
management to reduce risk information sheet
of infection.
Aloe vera, notoginseny, diclofenac, and
heparin gel 1000 IU showed a level of
Effectiveness of topical evidence and a moderate degree of
treatments in hospitalized recommendation. Heparin gel is the only
patients with phlebitis compound indicated by the Spanish
Systematic review of clinical
Martín-Gil et al., 2017 [6] secondary to peripheral Agency of Medicines and Medical 10/11 **** DE*: 1b DR: A
trials and reviews
venous catheterisation to Products to treat post-infusion phlebitis;
improve or resolve signs notoginseny is not marketed in the
and symptoms. Western world; and diclofenac is an
anti-inflammatory used in
various pathologies.
c. RESULTS FROM QUALITATIVE STUDIES
JBI Synthesis of the
Year and Author Research Question Methodology Results Critical Reading
Evidence
Nursing practices that differ from
scientific evidence; influence from
What are the PVC-related institutional dimensions; characteristics
nursing practices for Qualitative study, of the sick and misinformation about
Salgueiro-Oliveira et al., DE*: 4b
identifying deviations from participants monitoring patient safety risk actions. Developing 9/11 ****
2019 [2] DR: A
available evidence on and interviews protocols and implementing continuing
phlebitis prevention? education are critical to acquiring skills,
correcting and providing safe and
quality assistance.
Healthcare 2021, 9, 611 9 of 24

Table 3. Cont.

d. RESULTS FROM DESCRIPTIVE STUDIES

JBI Synthesis of the
Year and Author Research Question Methodology Results Critical Reading
Evidence
For the prevention of phlebitis, an
educational intervention through team
training has the potential to reduce 50%
of cases in peripheral intravenous
therapy. Phlebitis rates/incidence are
used as an indicator of nursing quality of
care. As best prevention practices, it is
suggested to use smaller calibre
cannulae, transparent dressings, and
professional knowledge of signs and
What are the characteristics of symptoms that warn of possible
Da Silva-Oliveira et al, phlebitis reported in a hospital Descriptive phlebitis. On the venous access site, a DE*: 4a
HIGH evidence *****
2016 [44] of the Sentinel Hospital quantitative study statistical association was found DR: A
Surveillance Network? between the back of the hand with more
grade I phlebitis, followed by antecubital
pit with higher number of grade II and
grade III phlebitis. It is advisable to
prioritize peripheral catheterisation in
upper limb blood vessels, as they are
safer. Avoid joint areas with greater
mobility, more prone to traumatic
mechanical phlebitis formation, and
control osmolarity and pH of medication
to reduce chemical phlebitis.
Healthcare 2021, 9, 611 10 of 24

Table 3. Cont.

e. RESULTS FROM CLINICAL PRACTICE GUIDELINES

Year and Author Research Question Methodology Results HICPAC Category AGREE
PVC insertion technique:
Handwash with antiseptic soap and
water if visibly dirty (40–60 s) or
alcoholic-based friction (20–30 s) if
visibly clean.
Avoid joint areas; wrist and antecubital
pit, since they have a higher incidence of
mechanical phlebitis.
To insert a PVC, 10–15 cm compressor
Guide to recommendations on above the puncture site, locate vein by
Torres-Muñoz et al., 2018 [4] nursing care of vascular Clinical Practice Guideline palping, and place the limb in decline to Category IA ** Recommended ***
accesses. favor venous filling. alcoholic
chlorhexidine solution at > 0.5% or
aqueous chlorhexidine at 2%. In cases of
hypersensitivity, use iodine solutions or
alcohol at 70%. PVC is covered with
transparent sterile dressing.
PVC Maintenance:
Reduce connections manipulations;
handle stopcocks or bio-connectors with
hygienic hand washing and clean gloves.
Healthcare 2021, 9, 611 11 of 24

Table 3. Cont.

- Selection of catheter and vein,

assess objective, duration, and
osmolarity of treatment, state of
venous sources, and professional
experience. Choose a catheter of
the least length and caliber
possible, without exceeding vein
calibre, to allow blood passage and
hemodilution of the preparations.
Antiseptic on clean skin, making
Vascular Access Nursing Care circles from inside to outside, and
Torres-Muñoz et al., 2018 [4] Clinical Practice Guideline let dry. Category IB ** Recommended ***
Recommendations Guide
- Evaluate insertion site daily. In
case of phlebitis, this is recorded in
patient history along with the
degree detected. Remove
blood-derived administration
systems at the end of transfusion.
PVC is only changed when
clinically justified; there are no
benefits on systematic change
every 72–96 h.

- It is not necessary to wear sterile

gloves as long as aseptic technique
Vascular Access Nursing Care is guaranteed. Dressing is placed
Torres-Muñoz et al., 2018 [4] Clinical Practice Guideline with clean gloves without touching Category IC ** Recommended ***
Recommendations Guide
the adhesive part and without
placing tie-shaped adhesive tapes.
Healthcare 2021, 9, 611 12 of 24

Table 3. Cont.

- Insert PVC into upper extremities.

If bleeding persists after insertion
of PVC, absorbent gauze dressing
may be placed and fixed until a
Vascular Access Nursing Care transparent dressing can be placed.
Torres-Muñoz et al., 2018 [4] Clinical Practice Guideline Category II ** Recommended ***
Recommendations Guide Suture fastening will be avoided.
The dressings are changed every 7
days, or if visibly soiled or damp.
Dressing change is recorded.

Before inserting a PVC, hand hygiene

with alcoholic-based solution or
antiseptic soap. Wear clean gloves.
Prepare skin with 2% alcoholic
chlorhexidine and allow to dry. Cover
with sterile, transparent, and
Prevention of complications
Martínez-Ortega et al., semi-permeable dressing to inspect
related to peripheral venous Clinical Practice Guideline Category IA ** Recommended ***
2019 [7] insertion site.
catheter for vascular access.
Change management systems and
connections every 4–7 days, and to
reduce risk of infection, clean access port
with antiseptic (alcoholic chlorhexidine
>0.5% or alcohol at 70%)
Remove any PVC that is not essential.
Healthcare 2021, 9, 611 13 of 24

Table 3. Cont.

Select PVC based on objective, expected

time of use, and known complications.
Select catheter of the smallest caliber and
shortest length possible. Avoid areas of
the joints (hand, wrist, and antecubital
pit), with increased risk of infiltration
Prevention of complications and injury from extravasation.
Martínez-Ortega et al.,
related to peripheral venous Clinical Practice Guideline Dressings will be changed every 7 days, Category IB ** Recommended ***
2019 [7]
catheter for vascular access. except in pediatric patients, where risk
of dislodging PVC is greater than the
advantages of changing dressings.
Remove PVC if signs of phlebitis,
infection, or malfunctioning appear. It is
recommended to use The Visual Scale of
Phlebitis Assessment (Maddox scale).
Prevention of complications It is recommended to use split septum
Martínez-Ortega et al., 2019
related to peripheral venous Clinical Practice Guideline valves against mechanical ones, which Category II ** Recommended ***
[7]
catheter for vascular access. have an increased risk of infection.
It is recommended to assess our patient’s
Assessment of the vascular
characteristics regularly, recognize risk
access site, determining type
Infusion Nurses Society, 2016 factors for bacterial, mechanical, or
of intervention, education Clinical Practice Guideline Category IB ** Recommended ***
[9] chemical phlebitis, and consider
about phlebitis for the patient,
pharmacological actions, also applying a
and response to treatment
warm compress and elevating the limb.
* Joanna Briggs Institute (JBI) degree of evidence (DE) and degree of recommendation (DR), ** Category of HICPAC recommendations, *** The Appraisal of Guidelines for Research and Evaluation (AGREE)
Instrument, **** Critical Appraisal Skills Programme Español (CASPe), ***** Berra et al. [24].
Healthcare 2021, 9, 611 14 of 24

The articles are classified as nursing interventions for the prevention of phlebitis or
for the treatment of phlebitis, both for nurses who apply care independently and for nurses
that follow guidelines and protocols.

3.1. Nursing Interventions for the Prevention of Phlebitis

Management and maintenance of intravenous therapy
• Protocol monitoring and continuous evaluation [28,29].
• Records need to include date of puncture, dressings used, professional performing the
procedure, date of change of PVC, puncture locations, number of puncture attempts,
intravenous medication in use, change of dressing, and next check-up [4,44].
• For intermittent flushing and locking of PVC, it is recommended to use saline solu-
tion (SS) before and after administration of medication by performing the positive
pressure technique [4,29]. According to the Flebitis Zero project, flushing heparin is
not recommended because it can cause thrombocytopenia [7]. A randomized clinical
trial reflected that continuous infusion of heparin into PVCs improved the duration of
permeability, reducing infusion failure and phlebitis. However, no statistically signif-
icant differences were found when heparin was used intermittently. If PVC is used
to obtain a blood sample, the use of diluted heparin is indicated [43]. Double-pump
syringes enable both medication and cleaning solution administration to reduce PVC
manipulation and complications [40].
• To prevent and treat phlebitis, Aloe vera, Matricaria chamomilla, and Xianchen (com-
posed of some components such as Fritillaria and Bletilla striata) can be used. The
application of Moist Exposed Burn Ointment (MEBO) for topical treatment of burn
injuries, containing sesame oil, β-sitosterol, Berberine, and other medicinal plants
(Coptis chinensis, Scutellaria baicalensis, Phellodendron chinese, and Papaver som-
niferum) [36] is also effective.
• Remove peripheral venous catheters if the patient develops signs of phlebitis (warmth, ten-
derness, erythema, or palpable venous cord), infection, or a malfunctioning catheter [7,45].
• Not performing a systematic catheter change every 72 to 96 h. It must be changed
when clinically justified. There are no significant differences in the percentage of
complications (phlebitis, occlusion...) between PVC that have been inserted less than
96 h and those that have been inserted for more than 96 h [4,46,47].
• Avoiding insertion into joint areas, wrist, and antecubital fossa, because there is a
higher incidence of mechanical phlebitis related to catheter movement [4].
• Replacing administration systems, extension cords, and accessories with a frequency
of more than 96 h and less than 7 days, when dirty or damaged connections are
observed, and whenever there is an accidental disconnection of the circuit [4].
• Withdrawing systems of blood administration and of blood products at the end of
transfusion [4].
• In adults, an upper-extremity site for catheter insertion must be used. Any catheter
inserted in a lower extremity must be replaced to an upper extremity site as soon as
possible [4].
• Using a 0.22-micron line filter to remove air and bacteria and small drug particles that
were not properly diluted. A filter is also required when the infusion of amiodarone
exceeds 24 h [48].
• Guiding patients and family members on signs and symptoms of phlebitis, during
infusion and post-infusion after extraction of PVC [2,31]. Educating patients on the
fact that ensuring proper care of PVC helps reduce risk of infection [17].

3.2. Asepsis
• Using alcoholic chlorhexidine solution at > 0.5% or aqueous chlorhexidine at 2%. In
cases of hypersensitivity, iodine solutions or alcohol at 70% may be used [4,17].
• Applying antiseptics to clean skin and complying with drying times (2% alcoholic
chlorhexidine: 30 s; non-alcoholic chlorhexidine and povidone–iodine: 2 min) [4].
Healthcare 2021, 9, 611 15 of 24

• Hygienic hand washing and usage of clean gloves for both punctures and equipment,
hubs, stopcocks, and bio-connectors handling. It is not necessary to wear sterile gloves
if the previously disinfected area is not touched again during the technique [4]. Using
disposable tourniquets can help reduce PVC contamination rates [49].
• Minimizing handling of connectors for infusion equipment [4].
• Protecting dressing and connectors in activities that may pose a risk of contamina-
tion [4].
• High incidence of phlebitis and infection of inserted PVCs has been found in emer-
gency areas. In these cases, it is recommended to replace the catheter within the first
48 h if aseptic technique could not be ensured [7,41].

3.3. Nursing Assessment

• Involving the patient in the choice of PVC and puncture site [2].
• Analyzing patient characteristics, prescribed medications (irritant and/or vesicant,
pH, and osmolarity), expected duration of the treatment, and other risk factors for the
onset of phlebitis, before opting for a PVC [4,30].
• Assessing the status of venous resources. Whenever possible, choose straight, palpable,
and well-filled vessels [4].
• Keeping the PVC insertion site visible [40,45]. Developing an observation table to
document the development of signs of phlebitis for early detection and decreased
discomfort and pain [50].
• Previously identifying comorbidities such as diabetes mellitus due to the changes in
the circulatory system caused by this disease [31].
• Asking the patient if there is pain/discomfort, heat, or burning at the insertion site [32].

3.4. Catheter
• Selecting the length and caliber of the catheters based on objective, expected time of
use, known infectious or non-infectious complications, experience of those who insert
and manage the catheter [7].
• Selecting a catheter of the least length and caliber possible, not exceeding the caliber
of the chosen vessel, to allow blood to pass into the vessel and favor the hemodilution
of the preparations to be infused [4,45].
• Using the minimum number of three-way stopcocks. Idle ports should always be
capped [4].
• Using only one of the ports of the three-way stopcock to place a bio-connector, where
medication solutions and bolus will be administered. The results of a prospective
experimental study indicate that using SwabCap significantly reduced connector con-
tamination from 43.7% to 0% (p = 0.006) [51]. If this cap is not available, the bio-connector
is disinfected with alcoholic chlorhexidine at >0.5% or 70% alcohol for 30 s [4,7].
• Teflon, silicone, or polyurethane elastomer catheters are safer than those of polyethy-
lene, polyvinyl hydrochloride, or steel needles, which might cause tissue necrosis if
extravasation occurs [43].

3.5. Dressing
• It is not advisable to bandage the site of the intravenous line. Sterile, transparent [45],
semipermeable adhesive dressing will be used to improve visibility of the insertion
site [7,32,52].
• The dressing should be placed aseptically, with clean or sterile gloves, without ex-
cessively touching the adhesive layer and without placing tie-shaped adhesive tapes
under the dressing. Wear sterile gloves for central and arterial devices [4].
• Changing dressings at least every 7 days, except in pediatric patients, where the risk
of moving the catheter is greater than the advantages derived from changing the
dressing [7]. Routine dressing change is not recommended, as it increases the risk of
colonization at the puncture site [49].
Healthcare 2021, 9, 611 16 of 24

• Replacing catheter site dressing if the dressing becomes damp, loosened, or visibly
soiled [7].
• If the site is bleeding or oozing, use gauze dressing until this is resolved [4].
• Ensuring correct securement or dressing to prevent dislodgement [4].
• Softly removing dressing, without moistening the puncture site [4].
• For catheter securement, products such as CliniFix simultaneously reduce the risk of
infection and trauma from cannula movement. Made with hydrocolloid adhesive, not
harmful to the skin, that can remain in place for up to 7 days without affecting the
integrity of the skin. In the presence of wound oozing, hydrocolloids absorb fluid and
form gel to help reduce the spread of infection [42].
• Using skin glue (cyanoacrylate) at the insertion site to improve catheter securement
and reduce rates of phlebitis and occlusion. Apply a drop at the insertion site and a
drop under the center of the catheter, allow to dry for 30 s, and place a dressing [33].
• Using the “I.V. House UltraDressing” in pediatric patients to increase catheter dwell
time, and to protect and stabilize PIVCs [34].

3.6. Nursing Interventions for the Treatment of Phlebitis

Nurse as a care prescriber
• Apply alternating hot and cold compresses to decrease erythema, edema, and pain.
The hot compress stimulates vasodilation by inducing optimal blood circulation and
promoting a faster wound-healing process. The cold compress stimulates vasocon-
striction and reduces edema [35].
• Apply compresses with 0.9% NaCl to stimulate anti-inflammatory response and
relieve pain, redness, swelling, and edema [35].
• Apply 10 drops (3 mL) of sesame oil (SO) twice daily for two weeks. Massage for 5
min within 10 cm of the place of phlebitis. Use a finger with a sterile glove to apply a
rotary technique. SO contains unsaturated fatty acids (linoleic acid, oleic acid) that
relieve pain by reducing prostaglandins and leukotriene. In addition, the SO has
lignans responsible for analgesic and anti-inflammatory effects [36].
• Administer chamomile extract (2.5%), as it has anti-inflammatory and anti-edema
properties. It is the most effective in the treatment of grade II phlebitis. The use of
topical chamomile showed that the incidence of phlebitis in patients treated with amio-
darone decreases significantly. Aqueous chamomile extract inhibits the production
of prostaglandins by the suppression of cyclooxygenase-2 (COX-2) and direct gene
expression of inhibition of COX-2 enzyme activity [37].
• Apply a compress with Burow solution at a temperature between 2 and 8 degrees
Celsius, and leave on for 20 min every 8 h. This formulation has as its main component
aluminium acetate, which is known for its astringent properties and ability to produce
the precipitation of proteins at the topical level. Based on observed results, the Burow
solution could be defined as an effective therapeutic alternative in the treatment of
post-infusion phlebitis [38].
• Apply marigold ointment every 8 h. Calendula/marigold flavonoids prevent his-
tamine release and prostaglandin production. In addition, they inhibit blood plasma
secretion in tissues, reduce the migration of white blood cells to the swelled area, and
prevent the growth of bacteria and fungi by reducing capillary permeability. In one
study, the application of marigold ointment decreased the severity of phlebitis in a
shorter period compared to using a wet and hot compress. It is proven to have anti-
inflammatory and antibacterial effects. Although calendula has an anti-inflammatory
effect similar to corticoids, it has none of its complications and is safe to use [39].

3.7. Nurses Following Protocols and Guidelines

• Topical treatments with Aloe vera or “Chamomilla Recutita” using wet compresses
at 38 degrees Celsius on the affected area. Apply topical diclofenac and "Essaven"
heparin gel. Other topical products such as notoginseny and 5 mg nitroglycerin
Healthcare 2021, 9, 611 17 of 24

patch accelerate the improvement of phlebitis symptoms, as compared to heparinoid

substances [6].
• Dilution of chemotherapeutic agents, immediate catheter removal, intermittent hep-
arin washing, prophylactic antibiotics, transparent dressings, topical application of
anti-inflammatory or corticosteroid agents, and application of a hot and/or wet com-
press are preventive and therapeutic approaches [36].
• There is no definitive treatment to prevent phlebitis; drugs such as heparin, corticos-
teroids, and piroxicam have been proposed as therapeutic agents [39].
In addition, Table 4 identifies the interventions found in the literature, their evidence
synthesis, and their correspondence with NIC nursing interventions.

Table 4. Correspondence with NIC interventions and DE and DR analysis with JBI.

Synthesis of
Result Interventions NIC [20]
the Evidence
DE*:3c
Protocol monitoring and continuous evaluation (6520) Health Screening
DR*: A
Records need to include date of puncture,
securement used, professional performing the
DE*: 4a (4200) Intravenous
procedure. When changing the PVC, record date,
DR: A therapy (i.v.)
site, number of puncture attempts, intravenous
medication in use.
(2314) Intravascular
Using sterile saline solution to secure the PVC, to DE*: 1c
medication
avoid heparin-induced thrombocytopenia. DR: A
administration (i.v.)
For intermittent flushing and locking, perform
(2314) Intravascular
the positive pressure technique to avoid a DE*: 2c
medication
possible suction effect or backflow when DR: A
administration (i.v.)
extracting the syringe.
Flushing stopcocks and hubs with normal saline
(4235) Phlebotomy:
solution. If PVC is used to obtain a blood sample, DR*: B
Cannulated Vessel
the use of diluted heparin is indicated.
Management and Using double-pump syringes to enable both (2314) Intravascular
maintenance of DE: 1c
medication and cleaning solution administration medication
intravenous therapy DR: A
to reduce PVC manipulation and complications. administration (i.v.)
DE*: 1b
To prevent and treat phlebitis, use Aloe vera, DR: A (3584) Skin care: topical
Matricaria chamomilla, or Xianchen. DE*: 1c treatments
DR: A
(4200) Intravenous
Removing any PVC that is not essential. Category IA **
therapy (i.v.)
Not performing a systematic catheter change
(4200) Intravenous
every 72 to 96 h. It must be changed when Category IB **
therapy (i.v.)
clinically justified.
Avoiding insertion into joint areas, wrist, and (4190) Intravenous
Category IA **
antecubital fossa. insertion (i.v.)
Replacing administration systems, extension (4200) Intravenous
Category IA **
cords, and accessories between 4 and 7 days. therapy (i.v.)
DE*: 3c
Guiding patients and family members on signs
DR*: A (6610) Risk identification
and symptoms of phlebitis after removing the
DE*: 1ª (5510) Health education
catheter and at hospital discharge.
DR: A
Healthcare 2021, 9, 611 18 of 24

Table 4. Cont.

Synthesis of
Result Interventions NIC [20]
the Evidence
Using alcoholic chlorhexidine solution at > 0.5% (4200) Intravenous
Category IA **
or aqueous chlorhexidine at 2% to wash skin. therapy (i.v.)
Applying antiseptic on clean skin, making circles (4200) Intravenous
Category IB **
from inside to outside, and let dry. therapy (i.v.)
Handling stopcocks, hubs, ports, and
Catheter asepsis (4200) Intravenous
bio-connectors with hygienic hand washing and Category IA **
therapy (i.v.)
clean gloves.
(4190) Intravenous
In cases such as those in emergency areas,
DE: 1c insertion (i.v.)
replace the catheter as soon as possible if aseptic
DR: A (4200) Intravenous
technique cannot be ensured.
therapy (i.v.)
(4190) Intravenous
DE*: 3b
Involving the patient in the choice of PVC. insertion (i.v.)
DR: A
(5510) Health education
Analysing patient characteristics, prescribed (6610) Risk identification
intravenous medications, expected duration of DE*: 5a (2314) Intravascular
the treatment, and other risk factors for the onset DR: A medication
of phlebitis, before opting for a PVC administration (i.v.)
Nursing assessment
Assessing osmolarity of treatment and state of (4190) Intravenous
Category IB **
venous sources when inserting the PVC. insertion (i.v.)
Previously identifying comorbidities such as
diabetes mellitus.
DE*: 4a (6610) Risk identification
Educating to provide with knowledge on signs
DR: A (5510) Health education
of phlebitis and facilitate early detection and
minimize complications.
Choosing a catheter based on estimated function, (4190) Intravenous
DR*: A
duration, and known complications. insertion (i.v.)
Choosing a catheter of the least length and (4190) Intravenous
Category IB **
caliber possible, without exceeding vein caliber. insertion (i.v.)
Using the minimum number of three-way (4200) Intravenous
Category IA **
Catheter stopcocks. Idle ports should always be capped. therapy (i.v.)
Using only one of the ports of the three-way
stopcock to place a bio-connector, where
intermittent medication solutions and bolus will (4235) Phlebotomy:
Category IA **
be administered. Protect with cap infused with Cannulated Vessel
alcoholic solution for one use or, if not possible,
disinfect the area with alcoholic solution for 30 s.
Using transparent adhesive sterile dressing to
(4190) Intravenous
achieve frequent and adequate intravenous Category IA **
insertion (i.v.)
inspection of the intravenous site.
Dressings will be changed every 7 days, except
in pediatric patients, where risk of dislodging (4190) Intravenous
Category IB **
PVC is greater than the advantages of changing insertion (i.v.)
Dressing dressings.
Using skin glue (cyanoacrylate) at the insertion
DE*: 1c (4190) Intravenous
site to improve catheter securement and reduce
DR: A insertion (i.v.)
rates of phlebitis and occlusion.
Using the "I.V. House UltraDressing" in pediatric
DE*: 1a (4190) Intravenous
patients to increase catheter dwell time, and to
DR: A insertion (i.v.)
protect and stabilize PIVCs.
Healthcare 2021, 9, 611 19 of 24

Table 4. Cont.

Synthesis of
Result Interventions NIC [20]
the Evidence
Applying alternating hot and cold compresses to DE*: 3c (1380) Heat/Cold
decrease erythema, edema, and pain. DR: A Application
Applying compresses with 0.9% NaCl to
DE*: 2c (1380) Heat/Cold
stimulate anti-inflammatory response and
DR: A Application
relieve pain, redness, swelling, and oedema.
Applying 10 drops (3 mL) of sesame oil (SO) DE*: 1c (3584) Skin care:
twice daily for two weeks. Massage for 5 min. DR: A topical treatments
Applying Moist Exposed Burn Ointment DE*: 1a (3584) Skin care:
Nurse as a care prescriber (MEBO) for topical treatment of burn injuries. DR: A topical treatments
Administering chamomile extract (2.5%), as it
DE*: 1b (3584) Skin care:
has anti-inflammatory and
DR: A topical treatments
anti-edema properties.
Applying marigold ointment every 8 h for DE*: 1c (3584) Skin care:
anti-inflammatory effect. DR: A topical treatments
Applying a compress with Burow solution at a
DE*: 3c (3584) Skin care:
temperature between 2 and 8 degrees Celsius,
DR: A topical treatments
and leave on for 20 min every 8 h.
Applying of anti-inflammatory or corticosteroid
DE*: 1a (3584) Skin care:
agents, and application of a hot and/or
DR: A topical treatments
wet compress.
DE*: 1c
Using corticosteroids and piroxicam to DR: A (2316) Medication
prevent phlebitis. DE*: 1ª Administration: Skin
DR: A
Nurse following protocols Applying topical treatments with aloe vera or
and guidelines "Chamomilla Recutita" using wet compresses at
38 degrees Celsius on the affected area.
(2316) Medication
Apply topical diclofenac and “Essaven” heparin
DE*: 1a Administration: Skin
gel for the treatment of phlebitis.
DR: A (3584) Skin care:
Topical products such as notoginseny and 5 mg
topical treatments
nitroglycerin patch accelerate the improvement
of phlebitis symptoms, as compared to
heparinoid substances.
* Joanna Briggs Institute (JBI) degree of evidence (DE) and degree of recommendation (DR), ** Category of HICPAC recommendations.

4. Discussion
The objective of this review was to identify available evidence on nursing interventions
for the prevention and treatment of phlebitis secondary to the insertion of a peripheral
venous catheter.
For the prevention of phlebitis, the greatest evidence found regarding asepsis is to
use >0.5% chlorhexidine preparation with alcohol or 2% aqueous chlorhexidine, perform
hygienic hand washing, and use clean gloves to handle connections and stopcocks (category
AI). Regarding the maintenance of PVC, the interventions with the greatest evidence
(category IA) are replacing extensions and administration sets between 4 and a maximum
of 7 days if they are not loosened or soiled, and using the fewest three-way stopcocks, one
of the ports with a bio-connector, and having the others capped [4]. Actions that promote
the efficacy and safety of intravenous therapy include maintenance of access, infusion
control, verification of signs of phlebitis during saline solution replacement and medication
administration, and constant monitoring [53,54]. It is recommended to remove any catheter
that is not essential (Category IA) [7]. Once discharged from hospital, it will be necessary
to warn the patient about signs of phlebitis after PVC removal [2] (DE 1a).
Healthcare 2021, 9, 611 20 of 24

Regarding the dressing, the greatest evidence obtained is the use of “IV House Ultra-
Dressing” in pediatric patients to increase dwell time and stabilize the catheter [34] (DE
IA). The dressing must be sterile, transparent, and semi-permeable for continuous visual
inspection of the catheter site [7] (Category IA). A novel technique is the use of medical
grade cyanoacrylate for catheter securement to reduce rates of phlebitis [33] (DE 1c).
Vein quality control through palpation and visual inspection can prevent phlebitis as
well as the nurse’s duration of hand hygiene and the clinical experience [55]. Regarding
the choice of veins, a controversy has been found, as some studies recommend the forearm
as it has a larger diameter and this reduces rates of phlebitis in the region, but there are
many others that claim that this region should be avoided, in addition to the joints and
wrist areas (category IA), for having a higher incidence of mechanical phlebitis related
to catheter movement [4,56]. A review of the literature concluded that veins from the
antecubital region are associated with lower rates of phlebitis, as compared to veins in the
hands. Therefore, although the back of the hand is considered an easily accessible venous
place, it is not indicated for prolonged venous therapy, and nurses are believed to need to
be trained in carrying out alternatives such as jugular vein venipuncture that has very low
rates of prevalence of phlebitis [44].
Although some studies, such as the one conducted by Circolini et al. (cited in Wei
et al. [57]), in which Cox’s analysis was used, showed that as the PVC’s dwell time increased
by 24 h, the risk of phlebitis also did so with an odds ratio of 1.05. Webster et al.’s [46]
team concluded in their clinical trial review that the catheter should be removed only when
clinically indicated, evaluating at every new shift to identify signs of phlebitis [46,57,58] early.
There are higher rates of phlebitis when larger caliber catheters are used, as they
increase attraction to the vessel wall, so the smallest possible length and caliber catheters
(Category IB) are recommended [4,56].
The nurse’s clinical judgment regarding the selection of a PVC should also involve
assessing comfort, anxiety, and restrictions in the patient’s day-to-day activities. The
number of venipuncture attempts is one of the quality indicators and shows patient
satisfaction for its sensory impact [59].
For the control and management of intravenous therapy, nurses should carry out a
protocol that includes recording all aspects related to the catheter and its maintenance (DE
4a and DR A) [28].
According to the studies consulted, the data show a higher proportion of complications
in peripheral venous catheters among women (p = 0.0300), patients 85 years of age or older
as compared to those under 65 (p = 0.0500), and when puncturing the forearm region as
compared to other regions (p ≤ 0.0001) [60].
Regarding saline flush, the effectiveness and safety of a solution of 0.9% of sodium
chloride was compared with heparin saline solution, and it was concluded that both agents
are equally effective and safe [14]. However, flushing PVC with normal saline prevents the
accumulation of bacteria, proteins, and platelets suspended in plasma; therefore, saline
flush prevents and reduces phlebitis [13] (DE 1c).
It is necessary to check that the prescription of intravenous medication can be admin-
istered peripherally, as many of these drugs are irritating. Regular evaluation is key to the
prevention and early detection of intravenous complications (DE 5a) [30,61].
In case the patient has phlebitis, nursing interventions with more evidence in their
application are Moist Exposed Burn Ointment (MEBO) for topical treatment of burn injuries,
Aloe vera, chamomilla recutita in wet compresses, topical diclofenac, “Essaven” heparin
gel, notoginseny, and 5 mg nitroglycerin patch and anti-inflammatory or corticosteroids
in a hot or wet compress (DE 1a) [6,36]. On the other hand, the application of marigold
ointment, piroxicam, and sesame oil has an evidence level of 1C [36,39].
Some limitations of this bibliographic review are the little available evidence on the
use of Burow’s solution as a treatment for phlebitis, despite its usual use in hospitals. This
review may contain limitations inherent to the search and selection process. Therefore, we
believe that further research and systematic review of the findings is needed.
Healthcare 2021, 9, 611 21 of 24

5. Conclusions
In conclusion, this review includes evidence-based interventions for the prevention
and treatment of phlebitis associated to the venous catheter. The need for nursing training
on the latest available evidence regarding the use and management of venous catheters
is highlighted. It is important that hospitals implement projects such as “Flebitis Zero”
so that nurses can rely and base their knowledge on them, thus providing quality care
to patients.

Author Contributions: Conceptualization, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-
C.; Data curation, A.G.-S., M.B.S.-G. and G.D.-C.; Formal analysis, A.G.-S., M.B.S.-G., M.E.C.-P.,
J.Á.R.-G., J.G.-S. and G.D.-C.; Investigation, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-
C.; Methodology, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.; Project administration,
A.G.-S., M.B.S.-G. and G.D.-C.; Resources, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.;
Software, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.; Supervision, A.G.-S., M.B.S.-G.,
M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.; Validation, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and
G.D.-C.; Visualization, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.; Writing—original
draft, A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C.; Writing—review and editing,
A.G.-S., M.B.S.-G., M.E.C.-P., J.Á.R.-G., J.G.-S. and G.D.-C. All authors have read and agreed to the
published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: All data is available within this article.
Acknowledgments: We would like to thank to the School of Nursing Nuestra Señora de Candelaria
of Tenerife, Spain, its teachers and board of directors, for their collaboration for the development of
this Final Degree Project, as well as for their educational and socializing work.
Conflicts of Interest: The authors declare no conflict of interest.

References
1. Urbanetto, J.S.; Peixoto, C.G.; May, T.A. Incidencia de flebitis durante el uso y después de la retirada de catéter intravenoso
periférico. Rev. Latino-Am. Enfermagem 2016, 24, e2746. [CrossRef]
2. Salgueiro-Oliveira, A.S.; Basto, M.L.; Braga, L.M.; Arreguy-Sena, C.; Melo, M.N.; Parreira, P.M. Nursing practices in peripheral
venous catheter: Phlebitis and patient safety. Texto Contexto-Enferm 2019, 28, e20180109. [CrossRef]
3. Enes, S.M.S.; Opitz, S.P.; Faro, A.R.M.d.C.d.; Pedreira, M.d.L.G. Phlebitis associated with peripheral intravenous catheters in
adults admitted to hospital in the Western Brazilian Amazon. Rev. Esc. Enferm. USP 2016, 50, 263–271. [CrossRef] [PubMed]
4. Torres-Muñoz, R.; Marín-Navarro, L.; Gallego-Sánchez, J.C. Cuidados de Enfermería en los Accesos Vasculares. Guía De
recomendaciones. Complejo Hospitalario Universitario de Badajoz. Área de Salud de Badajoz. 2018. Available online:
https://www.areasaludbadajoz.com/Calidad_y_Seguridad_2016/Cuidados_enfermeria_accesos_vasculares.pdf (accessed on 12
December 2020).
5. Tork-Torabi, M.; Namnabati, M.; Allameh, Z.; Talakoub, S. Vancomycin Infusion Methods on Phlebitis Prevention in Children.
Iran. J. Nurs. Midwifery Res. 2019, 24, 432–436. [CrossRef]
6. Martín-Gil, B.; Fernández-Castro, M.; López-Vallecillo, M.; Peña-García, I. Efectividad del tratamiento tópico de la flebitis
secundaria a la cateterización periférica: Una revisión sistemática. Enferm. Glob. 2017, 16, 491–507. [CrossRef]
7. Martínez-Ortega, C.; Suárez Mier, B.; Cantero, M.; Llinás, M.; Plan Nacional Resistencia Antibióticos. Prevención de Com-
plicaciones Relacionadas con Accesos Vasculares de Inserción Periférica. Programa Flebitis Zero. Ministerio de Sanidad,
Consumo y Bienestar Social. Agencia Española de Medicamentos y Productos Sanitarios. 2019. Available online: http:
//www.resistenciaantibioticos.es/es/system/files/content_images/programa_flebitis_zero.pdf (accessed on 12 February 2021).
8. Ray-Barruel, G.; Cooke, M.; Mitchell, M.; Chopra, V.; Rickrad, C.M. Implementing the I-DECIDED clinical decision-making tool
for peripheral intravenous catheter assessment and safe removal: Protocol for an interrupted time-series study. BMJ Open 2018,
8, e021290. [CrossRef]
9. Infusion Nurses Society. Infusion Nursing Standards of Practice. J. Infus. Nurs. 2016, 36, 1–159.
Healthcare 2021, 9, 611 22 of 24

10. Ortiz del Río, C.A.; Pérez de la Blanca, E.B.; Buzón Barrera, M.L.; Calderón Sandubete, E.; Carrero Caballero, M.C.; Carrión
Camacho, M.R.; Luna Rodríguez, M.E.d.; García Aguilar, R.; García Díez, R.; García Fernández, F.P.; et al. Guía de Práctica
Clínica Sobre Terapia Intravenosa con Dispositivos no Permanentes en Adultos. Ministerio de Sanidad, Servicios Sociales e
Igualdad. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA). 2014. Available online: https://www.aetsa.
org/publicacion/guia-de-practica-clinica-sobre-terapia-intravenosa-con-dispositivos-no-permanentes-en-adultos/ (accessed on
12 February 2021).
11. Nickel, B. Peripheral Intravenous Access: Applying Infusion Therapy Standards of Practice to Improve Patient Safety. Crit. Care
Nurse 2019, 39, 61–71. [CrossRef]
12. Atay, S.; Sen, S.; Cukurlu, D. Phlebitis-related peripheral venous catheterization and the associated risk factors. Niger. J. Clin.
Pract. 2018, 21, 827–831. [CrossRef]
13. Eghbali-Babadi, M.; Ghadiriyan, R.; Hosseini, S.M. The effect of saline lock on phlebitis rates of patients in cardiac care units. Iran.
J. Nurs. Midwifery Res. 2015, 20, 496–501. [CrossRef]
14. Milutinović, D.; Simin, D.; Zec, D. Risk factor for phlebitis: A questionnaire study of nurses’ perception. Rev. Lat. Am. Enferm.
2015, 23, 677–684. [CrossRef]
15. Furlan, M.S.; Costa-Lima, A.F. Direct cost of procedures for phlebitis treatment in an Inpatient Unit. Rev. Esc. Enferm. USP 2020,
54, e03647. [CrossRef]
16. Chiu, P.C.; Lee, Y.H.; Hsu, H.T.; Fneg, Y.T.; Lu, I.C.; Chiu, S.L.; Cheng, K.I. Establish a perioperative check forum for peripheral
intravenous access to prevent the occurrence of phlebitis. Kaohsiung J. Med. Sci. 2015, 31, 215–221. [CrossRef]
17. Osti, C.; Khadka, M.; Wosti, D.; Gurung, G.; Zhao, Q. Knowledge and practice towards care and maintenance of peripheral
intravenous cannula among nurses in Chitwan Medical College Teaching Hospital, Nepal. Nurs. Open 2019, 6, 1006–1012.
[CrossRef]
18. Ministerio de Ciencia e Innovación. Orden Cin/2134/2008, de 3 de Julio, Por la Que se Establecen los Requisitos para la
Verificación de los Títulos Universitarios Oficiales que Habiliten para el Ejercicio de la Profesión de Enfermero. BOE Num 174, de
19 de Julio de 2008. Available online: https://www.boe.es/eli/es/o/2008/07/03/cin2134 (accessed on 18 May 2021).
19. Herdman, T.H.; Kamitsuru, S. (Eds.) NANDA International Nursing Diagnoses: Definition and Clasification 2018–2020, 11th ed.;
Thieme Medical Publishers Inc.: New York, NY, USA, 2017.
20. Butcher, H.K.; Bulechek, G.M.; Dochrterman, J.M.; Wagner, C. Clasificación de Intervenciones de Enfermería (NIC), 7th ed.; Elsevier:
Barcelona, Spain, 2018.
21. Arksey, H.; O’Malley, L. Scoping studies: Towards a methodological framework. Int. J. Soc. Res. Methodol. 2005, 8, 19–32.
[CrossRef]
22. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [CrossRef]
23. Santamaría-Olmo, R. Programa de habilidades en Lectura Crítica Español (CASPe). Nefroplus 2017, 9, 100–101.
24. Berra, S.; Elorza-Ricart, J.M.; Estrada, M.D.; Sánchez, E. Instrumento para la lectura crítica y la evaluación de estudios epi-
demiológicos transversales. Gac. Sanit. 2008, 22, 492–497. [CrossRef]
25. Levac, D.; Colquhoun, H.; O’Brien, K.K. Scoping studies: Advancing the methodology. Implement. Sci. 2010, 5, 69. [CrossRef]
26. Flórez-Gómez, I.D.; Montoya, D.C. Las guías de práctica clínica y el instrumento AGREE II. Rev. Colomb. Ppsiquiat. 2011, 40,
563–576. [CrossRef]
27. Manterola, C.; Asenjo-Lobos, C.; Otzen, T. Jerarquización de la evidencia: Niveles de evidencia y grados de recomendación de
uso actual. Rev. Chil. Infectol. 2014, 31, 705–718. [CrossRef]
28. Jordan, Z.; Lockwood, C.; Munn, Z.; Aromataris, E. The update Joanna Briggs Institute Model of Evidence Based Healthcare. Int.
J. Evid. Based Healthc. 2019, 17, 58–71. [CrossRef]
29. Reichembach-Danski, M.T.; Mingorance, P.; Athanasio-Johann, D.; Adami-Vayego, S.; Lind, J. Incidence of local complications
and risk factors associated with peripheral intravenous catheter in neonates. Rev. Esc. Enferm. USP 2016, 50, 22–28. [CrossRef]
[PubMed]
30. Braga, L.M.; Parreira, P.M.; Salgueiro-Oliveira, A.S.; Mendes-Mónico, L.S.; Arreguy-Sena, C.; Henriques, M.A. Flebitis e
infiltración: Traumas vasculares asociados al catéter venoso periférico. Rev. Lat. Am. Enfermagem 2018, 26, e3002. [CrossRef]
31. Rosário-Pereira, M.S.; de Oliveria-Cunha, A.T.; Almeida-Lima, E.F.; Ferreira-Santos, T.F.; Batista-Portugal, F. La Seguridad del
paciente en el contexto de las flebitis notificadas en un hospital universitario. Rev. Epidemiol. Controle Infecção 2019, 9, 1–7.
[CrossRef]
32. Lim, E.Y.P.; Wong, C.Y.W.; Kek, L.K.; Suhairi, S.S.B.M.; Yip, W.K. Improving the Visibility of Intravenous (IV) Site in Pediatric
Patients to Reduce IV Site Related Complications-An Evidence-based Utilization Project. J. Pediatr. Nurs. 2018, 41, e39–e45.
[CrossRef]
33. Bugden, S.; Shean, K.; Scott, M.; Mihala, G.; Clark, S.; Johnstone, C.; Fraser, J.F.; Rickard, C.M. Skin Glue Reduces the Failure Rate
of Emergency Department-Inserted Peripheral Intravenous Catheters: A Randomized Controlled Trial. Ann. Emerg. Med. 2016,
68, 196–201. [CrossRef]
34. Büyükyılmaz, F.; Şahiner, N.C.; Cağlar, S.; Eren, H. Effectiveness of an Intravenous Protection Device in Pediatric Patients on
Catheter Dwell Time and Phlebitis Score. Asian Nurs. Res. 2019, 13, 236–241. [CrossRef]
Healthcare 2021, 9, 611 23 of 24

35. Annisa, F.; Nurhaeni, N.; Wanda, D. Warm Water Compress as an Alternative for Decreasing the Degree of Phlebitis. Compr. Child
Adolesc. Nurs. 2017, 40 (Suppl. 1), 107–113. [CrossRef]
36. Shamloo, M.B.B.; Nasiri, M.; Maneiy, M.; Dorchin, M.; Mojab, F.; Bahrami, H.; Naseri, M.S.; Kiarsi, M. Effects of topical sesame
(Sesamum indicum) oil on the pain severity of chemotherapy-induced phlebitis in patients with colorectal cancer: A randomized
controlled trial. Complement Ther. Clin. Pract. 2019, 35, 78–85. [CrossRef] [PubMed]
37. Sharifi-Ardani, M.; Yekefallah, L.; Asefzadeh, S.; Nassiri-Asl, M. Efficacy of topical chamomile on the incidence of phlebitis due to
an amiodarone infusion in coronary care patients: A double-blind, randomized controlled trial. J. Integr. Med. 2017, 15, 373–378.
[CrossRef]
38. García-Quintanilla, L.; Otero-Barreiro, M.; González-Barcia, M.; Virgós-Lamela, A.; Rodríguez-Prada, M.; Lamas, M.; Fernández-
Ferreiro, A. Estudio de la Utilización, Eficacia y Seguridad de la Solución de Burow en el tratamiento de la flebitis. Rev. Ofil Ibero
Lat. Am. J. Health Syst. Pharm. 2018, 28, 199–202.
39. Jourabloo, N.; Nasrabadi, T.; Ebrahimi-Abyaneh, E. Comparing the effect of warm moist compress and Calendula ointment on
the severity of phlebitis caused by 50% dextrose infusion: A clinical trial. Med. Surg. Nurs. 2017, 6, 21–26.
40. Parreira, P.; Sousa, L.B.; Marques, I.A.; Santos-Costa, P.; Braga, L.M.; Cruz, A.; Salgueiro-Oliveira, A. Double-chamber syringe
versus classic syringes for peripheral intravenous drug administration and catheter flushing: A study protocol for a randomised
controlled trial. Trials 2020, 21, 78. [CrossRef]
41. Pérez-Granda, M.J.; Bouza, E.; Pinilla, B.; Cruces, R.; González, A.; Millán, J.; Guembe, M. Randomized clinical trial analyzing
maintenance of peripheral venous catheters in an internal medicine unit: Heparin vs. saline. PLoS ONE 2020, 15, e0226251.
[CrossRef]
42. Higgingson, R. IV cannula securement: Protecting the patient from infection. Br. J. Nurs. 2015, 24, S23–S28. [CrossRef]
43. Chau, J.; Pellowe, C.; Instituto Joanna Briggs. Manejo de los dispositivos intravasculares periféricos. Best Pract. 2008, 12, 1–4,
ISSN 1329-1874.
44. Da Silva-Oliveira, E.C.; Barros-de Oliveira, A.P.; de Oliveira, R.C. Caracterización de flebitis notificada a la gestión de riesgos en
la red centinela hospitalaria. Rev. Baiana Enferm. 2016, 1–9. [CrossRef]
45. Mattox, E.A. Complications of Peripheral Venous Access Devices: Prevention, Detection, and Recovery Strategies. Crit. Care
Nurse 2017, 37, e1–e14. [CrossRef]
46. Webster, J.; Osborne, S.; Rickard, C.M.; Marsh, N. Clinically-indicated replacement versus routine replacement of peripheral
venous catheters. Cochrane Database Syst. Rev. 2019, 23, CD007798. [CrossRef]
47. Gilton, L.; Seymour, A.; Baker, R.B. Changing Peripheral Intravenous Catheter Sites When Clinically Indicated: An Evidence-Based
Practice Journey. Worldviews Evid. Based Nurs. 2019, 16, 418–420. [CrossRef] [PubMed]
48. Oragano, C.A.; Patton, D.; Moore, Z. Phlebitis in Intravenous Amiodarone Administration: Incidence and Contributing Factors.
Crit. Care Nurs. 2019, 39, 1–12. [CrossRef] [PubMed]
49. Parreira, P.; Serambeque, B.; Costa, P.S.; Mónico, L.S.; Oliveira, V.; Sousa, L.B.; Gama, F.; Bernardes, R.A.; Adriano, D.; Marques,
I.A.; et al. Impact of an Innovative Securement Dressing and Tourniquet in Peripheral Intravenous Catheter-Related Complications
and Contamination: An Interventional Study. Int. J. Environ. Res. Public Health 2019, 16, 3301. [CrossRef]
50. Mandal, A.; Raghu, K. Study on incidence of phlebitis following the use of peripheral intravenous catheter. J. Fam. Med. Prim.
Care 2019, 8, 2827–2831. [CrossRef]
51. Gutiérrez-Nicolás, F.; Nazco-Casariego, G.J.; Viña-Romero, M.M.; González-García, J.; Ramos-Diaz, R.; Perez-Perez, J.A. Reducing
the degree of colonisation of venous access catheters by continuous passive disinfection. Eur. J. Hosp. Pharm. 2016, 23, 131–133.
[CrossRef]
52. Corley, A.; Ullman, A.J.; Mihala, G.; Ray-Barruel, G.; Ray-Barruel, G.; Alexandrou, E.; Rickard, C.M. Peripheral intravenous
catheter dressing and securement practice is associated with site complications and suboptimal dressing integrity: A secondary
analysis of 40,637 catheters. Int. J. Nurs. Stud. 2019, 100. [CrossRef]
53. Lemos-Alves, J.; Mendes-Rodrígues, C.; Velloso-Antunes, A. Prevalence of Phlebitis in a Clinical Inpatient Unit of a High-
complexity Brazilian University Hospital. Rev. Bras. Ciências Saúde 2018, 22, 231–236.
54. Roman-Ros, A.C.; Ramos-Oliveira, D.; Debon, R.; Scaratti, M. Intravenous therapy in hospitalized older adults: Care evaluation.
Cogitare Enferm 2017, 2, e49989.
55. Lee, S.; Kim, K.; Kim, J.S. A Model of Phlebitis Associated with Peripheral Intravenous Catheters in Orthopedic Inpatients. Int. J.
Environ. Res. Public Health. 2019, 16, 3412. [CrossRef]
56. Loureiro-Buzatto, L.; Pinna-Massa, G.; Sorgini-Peterlini, M.A.; Yamaguchi-Whitaker, I. Factors associated with phlebitis in elderly
patients with intravenous infusion. Acta. Paul. Enferm. 2016, 29, 260–266. [CrossRef]
57. Wei, T.; Li, X.; Yue, Z.; Chen, Y.; Wang, Y.; Yuan, Z.; Lin, Q.; Tan, Y.; Peng, S.; Li, X. Catheter Dwell Time and Risk of Catheter
Failure in Adult Patients With Peripheral Venous Catheters. J. Clin. Nurs. 2019, 28, 4488–4495. [CrossRef]
58. Urbanetto, J.S.; Minuto-Muniz, F.O.; Martis da Silva, R.; Christo de Freitas, A.P.; Ribeiro de Oliveira, A.P.; Ramos dos Santos, J.C.
Incidence of phlebitis and post-infusion phlebitis in hospitalised adults. Rev. Gaúcha Enferm. 2017, 38, e58793.
59. Braga, L.M.; Salgueiro-Oliveira, A.S.; Pereira Henriques, M.A.; Arreguy-Sena, C.; Pianetti Albergaria, V.M.; Dinis-Parreira, P.M.
Cateterismo venoso periférico: Comprensión y evaluación de las prácticas de enfermería. Texto Context-Enferm. 2019, 28, e20180018.
[CrossRef]
Healthcare 2021, 9, 611 24 of 24

60. Reichembach Danski, M.T.; Johann, D.A.; Vayego, S.A.; Rodrigues-Lemes de Oliveira, G.; Lind, J. Complications related to the
use of peripheral venous catheters: A randomized clinical trial. Acta. Paul. Enferm. 2016, 29, 84–92.
61. Ray-Barruel, G. Infection Prevention: Peripheral Intravenous Catheter Assessment and Care. Aust. Nurs. Midwifery J. 2017, 24, 34.